Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
CONCLUSIONS: The results of this study demonstrated that AE signals differ among the five BCR-ABL1 TKIs. Furthermore, each BCR-ABL1 TKI displayed several new signals. These findings provide valuable information for clinicians aiming to reduce the risk of AEs during BCR-ABL1 TKI treatment.PMID:38395895 | PMC:PMC10885429 | DOI:10.1186/s40360-024-00741-x
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Authors: Dehua Zhao Xiaoqing Long Jisheng Wang Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Drugs & Pharmacology | Gastroenterology | Gleevec | Nilotinib | Respiratory Medicine | Study | Tasigna | Toxicology